Diabetes Treatment — Bridging the Divide
- 12 April 2007
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (15) , 1499-1501
- https://doi.org/10.1056/nejmp078030
Abstract
In the simplest terms, diabetes mellitus results when pancreatic beta cells are unable to maintain adequate insulin secretion to prevent hyperglycemia. A combination of genetic and environmental factors causes the underlying beta-cell failure. In type 1 diabetes, a T-cell–mediated autoimmune response against beta cells appears to be the main disease mechanism, whereas insulin resistance is the key metabolic abnormality in type 2 diabetes. Yet the way in which insulin resistance triggers beta-cell failure remains obscure. The report by Larsen et al. in this issue of the Journal (pages 1517–1526) provides insight into a shared mechanism of beta-cell dysfunction in type . . .Keywords
This publication has 5 references indexed in Scilit:
- Interleukin-1–Receptor Antagonist in Type 2 Diabetes MellitusNew England Journal of Medicine, 2007
- Cardiac death in a patient with adult-onset Still's disease treated with the interleukin 1 receptor inhibitor anakinraAnnals of the Rheumatic Diseases, 2007
- Inflammation and metabolic disordersNature, 2006
- IL‐1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?FEBS Letters, 2006
- Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration?Diabetologia, 2005